Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts
Andover, Mass. – November 5, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2026.
Third Quarter 2026 Financial Highlights
•Total revenue of $203.0 million, up 41%, including organic revenue growth* of 35%
•Product revenue of $113.4 million, up 29%, and service revenue of $89.6 million, up 60%, including organic service revenue growth* of 43%
•Net income of $17.1 million or $0.46 per diluted share in the third quarter of 2026
•Adjusted net income* of $18.9 million or $0.51 per diluted share in the third quarter of 2026
•Raises full-year 2026 revenue guidance to between $764-$774 million, inclusive of approximately $14 million from PAD Aviation
Recent Business Highlights
•Completed enrollment in Part A of the Next-Generation Organ Care System (OCS) ENHANCE Heart trial (September) and received U.


